Eosinophilic Granulomatosis With Polyangiitis (EGPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Eosinophilic Granulomatosis With Polyangiitis (EGPA) Market Outlook
Thelansis’s “Eosinophilic
Granulomatosis With Polyangiitis (EGPA) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Eosinophilic
Granulomatosis With Polyangiitis (EGPA) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Eosinophilic
Granulomatosis With Polyangiitis (EGPA) Overview
Eosinophilic
granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome
or allergic granulomatosis and angiitis, is a rare and severe form of
anti-neutrophil cytoplasm antibody-associated vasculitis characterized by
eosinophil-rich granulomatous inflammation and small to medium-sized vessel
vasculitis. It is an autoimmune disorder that affects multiple systems in the
body and is often associated with bronchial asthma and tissue eosinophilia. The
exact cause of EGPA is unknown, but it is triggered by various factors such as
allergens, infections, vaccinations, and drugs. It typically affects people
between the ages of 7 and 74, with no gender or ethnic predilection. The
disease progresses through three stages: the prodromal stage, characterized by
asthma or allergic rhinitis; the eosinophilic stage, characterized by excess
circulating eosinophils and involvement of multiple organ systems; and the
vasculitis phase, characterized by life-threatening vasculitis. The median age
at the onset of EGPA is between 49 and 59 years, and about 90% of patients have
a history of bronchial asthma. Differential diagnoses for EGPA include other
small vessel vasculitides and eosinophilic disorders such as parasitic
infections, drug allergies, haematological malignancies, eosinophilic
pneumonia, and allergic bronchopulmonary mycosis.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment